Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles CTAs Hit Trouble as Market Trends Reverse Stephen Taub The Returns Gap Shows Investors Can't Stop Chasing Performance James Comtois Why Flat Gold During Inflation Points to Fed Action Sponsored by CME Group